Open Access

Chairman’s welcome and introduction: the mandate for improving residual cardiovascular disease risk reduction in patients with adversely elevated LDL-C

Topic: Lipids
Sponsored by Sanofi US and Regeneron Pharmaceuticals

Congress Presentation

About the speaker

Professor Deepak Bhatt

Icahn School of Medicine at Mount Sinai, New York (United States of America)
39 presentations
7 followers

4 more presentations in this session

What do recent landmark, cardiovascular outcome trials evaluating PCSK9 inhibition in high risk patient populations teach us?

Speaker: Professor P. Steg (Paris, FR)

Thumbnail

Guidelines and the role of non-statin therapies for ASCVD reduction in high risk patients - Addressing statin intolerance and poor target LDL-C goal attainment

Speaker: Professor J. Jukema (Leiden, NL)

Thumbnail

Getting real world and “hands on” in patients with elevated LDL-C and high risk features for atherosclerotic cardiovascular disease — Case management sessions.

Speaker: Professor D. Bhatt (New York, US)

Thumbnail

Interactive question and answer session - PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease.

Speaker: Professor D. Bhatt (New York, US)

Thumbnail

Access the full session

PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease

Speakers: Professor D. Bhatt, Professor P. Steg, Professor J. Jukema, Professor D. Bhatt, Professor D. Bhatt
Thumbnail

About the event

Image

ESC Congress 2018

7 November - 29 August 2018

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb